Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)

Editor

Personal info

View

About

Terms

Javascript disabled

Please enable Javascript support in your browser to use this application.

Instructions on how to enable JavaScript on different browsers can be found here: http://www.google.com/support/bin/answer.py?answer=23852.

[edit this page]

Okpala, I. et al.

Pilot study of omega-3 fatty acid supplements in sickle cell disease.

Okpala I, Ibegbulam O, Duru A, Ocheni S, Emodi I, Ikefuna A, Umar G, Asinobi I, Madu A, Okoye A, Nwagha T, Oguonu U, Uamai I, Agwu O, Nonyelu C, Anike U, Agu K, Anigbo C, Chukwura A, Ugwu O, Herrada S. Pilot study of omega-3 fatty acid supplements in sickle cell disease. APMIS 2011; 119: 442-8. In a previous retrospective study, it was observed that the greater the amounts of the omega-3 fatty acids eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) in the blood, the lesser the number of complications of sickle cell disease (SCD) and the higher the steady state haemoglobin level. SCD causes ischaemia-reperfusion injury and inflammation; which can be ameliorated by a metabolite of DHA that down-regulates expression of pro-inflammatory genes. The objectives of this prospective pilot study were to evaluate the effects of DHA and EPA supplements in SCD, and test the hypothesis that these effects are mediated partly by reducing inflammation. Oral DHA and EPA supplements were given to 16 SCD patients for 6 months. We then compared pre- and post-supplementation values of number of crisis, steady state Hb, plasma unconjugated bilirubin and three indices of inflammation: plasma interleukin-6, blood neutrophil and platelet counts. There was a significant reduction in the plasma level of unconjugated bilirubin, and the number of sickle cell crisis; but not in the markers of inflammation. The pilot data suggest that DHA and EPA supplements reduce the number of crisis and steady state haemolysis in SCD; but provide no evidence that these effects are mediated by reducing inflammation.[1]

References

Pilot study of omega-3 fatty acid supplements in sickle cell disease. Okpala, I., Ibegbulam, O., Duru, A., Ocheni, S., Emodi, I., Ikefuna, A., Umar, G., Asinobi, I., Madu, A., Okoye, A., Nwagha, T., Oguonu, U., Uamai, I., Agwu, O., Nonyelu, C., Anike, U., Agu, K., Anigbo, C., Chukwura, A., Ugwu, O., Herrada, S. APMIS (2011) [Pubmed]

Annotations and hyperlinks in this abstract are from individual authors of WikiGenes or automatically generated by the WikiGenes Data Mining Engine. The abstract is from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.About WikiGenes Open Access Licence Privacy Policy Terms of Use apsburg

The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.